Skip to main content
Figure 5 | BMC Cancer

Figure 5

From: WRAP53 is an independent prognostic factor in rectal cancer- a study of Swedish clinical trial of preoperative radiotherapy in rectal cancer patients

Figure 5

Schematic illustration of WRAP53 in colon/rectal cancer. In rectal cancer patients WRAP53 levels are significantly enhanced in primary tumor compared to normal mucosa, and then slightly decreased in metastatic tumors compared to primary tumors (A). Preoperative radiotherapy may inhibit the action of WRAP53 by reducing WRAP53 expression, subsequently increasing apoptotic activity or/and directly inducing apoptosis, leading to low local/distant recurrence, and eventually improve patients’ survival (B). In colon cancer cells WRAP53 blocks apoptosis and survivin protein, which are the defense mechanisms against tumor formation. This effect of WRAP53 may eventually leads to development and progression of a tumor. Alternatively, overexpression of WRAP53 could directly lead to malignant transformation of normal cells by other unknown mechanisms (C).

Back to article page